In addition, apremilast effectively reduced the severity of both mAb-induced arthritis and CIA in BALB/c and DBA/1 mice, respectively, over 10 days post onset, without any evident side effects, often associated with classical PDE4 inhibitors such as rolipram. Here, PDE4A is linked to arthritic joint disease.